Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
1.
Int J Mol Sci ; 20(17)2019 Aug 27.
Artículo en Inglés | MEDLINE | ID: mdl-31461836

RESUMEN

Platelets are megakaryocyte-derived fragments lacking nuclei and prepped to maintain primary hemostasis by initiating blood clots on injured vascular endothelia. Pathologically, platelets undergo the same physiological processes of activation, secretion, and aggregation yet with such pronouncedness that they orchestrate and make headway the progression of atherothrombotic diseases not only through clot formation but also via forcing a pro-inflammatory state. Indeed, nuclear factor-κB (NF-κB) is largely implicated in atherosclerosis and its pathological complication in atherothrombotic diseases due to its transcriptional role in maintaining pro-survival and pro-inflammatory states in vascular and blood cells. On the other hand, we know little on the functions of platelet NF-κB, which seems to function in other non-genomic ways to modulate atherothrombosis. Therein, this review will resemble a rich portfolio for NF-κB in platelets, specifically showing its implications at the levels of platelet survival and function. We will also share the knowledge thus far on the effects of active ingredients on NF-κB in general, as an extrapolative method to highlight the potential therapeutic targeting of NF-κB in coronary diseases. Finally, we will unzip a new horizon on a possible extra-platelet role of platelet NF-κB, which will better expand our knowledge on the etiology and pathophysiology of atherothrombosis.


Asunto(s)
Plaquetas/metabolismo , FN-kappa B/metabolismo , Animales , Antiinflamatorios/farmacología , Plaquetas/efectos de los fármacos , Plaquetas/fisiología , Humanos , FN-kappa B/genética , Activación Plaquetaria , Inhibidores de Agregación Plaquetaria/farmacología
2.
Chem Senses ; 38(7): 577-84, 2013 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-23811013

RESUMEN

Anxiety can either impair or enhance performance depending on the context. Increased sensitivity to threat seems to be an important feature of sensory processing in anxiety since anxious individuals tend to be more attentive to threatening visual stimuli. Evidence of anxiety effects in olfaction is rare; though alterations of olfactory performance in psychiatric patients and some effects of trait and state anxiety on olfactory performance have been reported. Our main objective was thus to investigate whether olfactory processing speed varies as a function of trait anxiety levels. We additionally investigated a possible preferential bias for unpleasant odors in highly anxious participants. Thirty-eight healthy adults participated in a simple odor detection task, where response times (RTs) and anxiety levels were measured. We compared RTs to a pleasant and an unpleasant food odor between high- and low-trait anxiety participants. We found that high-trait anxiety participants detected both odors faster than low-trait anxiety participants, independently of odor pleasantness. Moreover, trait anxiety levels significantly correlated with reaction times to both odors, indicating that trait anxiety but not odor pleasantness influences olfactory detection speed. These findings provide new insights into olfactory processing in healthy adults showing how various levels of trait anxiety affect the olfactory modality.


Asunto(s)
Ansiedad , Odorantes , Percepción Olfatoria/fisiología , Adolescente , Adulto , Animales , Femenino , Peces , Fragaria , Humanos , Masculino , Experimentación Humana no Terapéutica , Tiempo de Reacción/fisiología , Adulto Joven
3.
J Am Heart Assoc ; 9(3): e013396, 2020 02 04.
Artículo en Inglés | MEDLINE | ID: mdl-32009527

RESUMEN

Background Antiplatelet therapy with aspirin (acetylsalicylic acid [ASA]) is less efficient in some coronary patients, which increases their risk of developing thrombosis. Elevated blood levels of thromboinflammatory mediators, like soluble CD40L (sCD40L), may explain such variabilities. We hypothesized that in the presence of elevated levels of sCD40L, the efficacy of ASA may vary and aimed to determine the effects of ASA on CD40L signaling and aggregation of platelets. Methods and Results The effects of ASA on CD40L-treated human platelets, in response to suboptimal concentrations of collagen or thrombin, were assessed at levels of aggregation, thromboxane A2 secretion, and phosphorylation of p38 mitogen-activated protein kinase, nuclear factor kappa B, transforming growth factor-ß-activated kinase 1, and myosin light chain. sCD40L significantly elevated thromboxane A2 secretion in platelets in response to suboptimal doses of collagen and thrombin, which was reversed by ASA. ASA did not inhibit the phosphorylation of p38 mitogen-activated protein kinase, nuclear factor kappa B, and transforming growth factor-ß-activated kinase 1, with sCD40L stimulation alone or with platelet agonists. sCD40L potentiated platelet aggregation, an effect completely reversed and partially reduced by ASA in response to a suboptimal dose of collagen and thrombin, respectively. The effects of ASA in sCD40L-treated platelets with collagen were related to inhibition of platelet shape change and myosin light chain phosphorylation. Conclusions ASA does not affect platelet sCD40L signaling but prevents its effect on thromboxane A2 secretion and platelet aggregation in response to collagen, via a mechanism implying inhibition of myosin light chain. Targeting the sCD40L axis in platelets may have a therapeutic potential in patients with elevated levels of sCD40L and who are nonresponsive or less responsive to ASA.


Asunto(s)
Aspirina/farmacología , Plaquetas/efectos de los fármacos , Ligando de CD40/farmacología , Cadenas Ligeras de Miosina/metabolismo , Inhibidores de Agregación Plaquetaria/farmacología , Agregación Plaquetaria/efectos de los fármacos , Plaquetas/metabolismo , Humanos , Fosforilación , Transducción de Señal , Tromboxano A2/metabolismo
4.
J Breast Cancer ; 23(1): 69-79, 2020 02.
Artículo en Inglés | MEDLINE | ID: mdl-32140271

RESUMEN

PURPOSE: Aberrant glycosylation of the histo-blood group antigens (including the angina bullosa haemorrhagica [ABH]) is often observed during malignant transformation in most types of carcinomas. Data concerning their ethnic distributions are diverse which explains why their biological characteristics have to be studied in different populations. Our aim was to analyze the expression of the histo-blood group (specifically the ABH) antigens in breast carcinoma. METHODS: The expression of the histo-blood group (specifically the ABH) antigens was studied in 109 patients with breast carcinoma using immunohistochemistry. Statistical analysis was performed using χ2 and Fisher analyses. RESULTS: The loss of expression of histo-blood group (ABH) antigens in breast carcinoma was observed in 81.13% of patients with blood group O, 37.93% with blood group A, and 96.30% with blood group B. One key finding of this study was that the loss of expression of the ABH antigen was also observed in normal tissues adjacent to the tumor. The loss of expression was associated with higher tumor grade (p < 0.05). Expression of H antigen was observed in 50% of cases with loss of expression of B antigen and was associated with human epidermal growth factor receptor 2 (HER2) overexpression (p < 0.05). The loss of H antigen in patients with blood group O was associated with estrogen receptor expression (p < 0.001). Incompatible A antigen in tumor was expressed in 20.75% of patients with blood group O. CONCLUSION: Loss of the ABH antigens correlated with the Scarff-Bloom-Richardson histologic grading. H antigen was associated with HER2 overexpression in breast cancer. However, further studies are needed to determine the role of incompatible A antigen in mammary carcinogenesis.

5.
J Am Heart Assoc ; 7(23): e03677, 2018 12 04.
Artículo en Inglés | MEDLINE | ID: mdl-30571597

RESUMEN

Background CD40 ligand (CD40L) is a thromboinflammatory molecule that predicts cardiovascular events. CD40L is a strong activator of nuclear factor kappa B (NF-κB) in platelets that primes and enhances platelet activation in response to thrombotic stimuli. In addition to its classical receptor CD40, CD40L binds αIIbß3, α5ß1, and αMß2 in various cell types. However, the function of the different CD40L receptors on platelets remains unexplored. The present study aims to identify the receptors of CD40L, involved in platelet NF-κB activation, their downstream signaling and their implication in platelet aggregation. Methods and Results We showed that platelets express CD40, αIIbß3, and α5ß1 and release CD40L in response to sCD40L stimulation. sCD40L alone dose-dependently induced platelet NF-κB activation; this effect was absent in CD40-/- mouse platelets and inhibited by the CD40 blockade, but was unaffected by the αIIbß3 or α5ß1 blockade in human platelets. sCD40L/CD40 axis activates transforming growth factor-ß-activated kinase 1 upstream of NF-κB. In functional studies, sCD40L alone did not affect platelet aggregation but potentiated the aggregation response in the presence of suboptimal doses of thrombin; this effect was abolished by CD40, transforming growth factor-ß-activated kinase 1, and NF-κB inhibitors. Conclusions CD40L primes platelets via signaling pathways involving CD40/transforming growth factor-ß-activated kinase 1/NF-κB, which predisposes platelets to enhanced activation and aggregation in response to thrombotic stimuli.


Asunto(s)
Plaquetas/efectos de los fármacos , Antígenos CD40/metabolismo , Ligando de CD40/farmacología , Quinasas Quinasa Quinasa PAM/metabolismo , FN-kappa B/metabolismo , Animales , Plaquetas/metabolismo , Ligando de CD40/metabolismo , Humanos , Masculino , Ratones , Ratones Endogámicos C57BL , Ratones Noqueados , Activación Plaquetaria/efectos de los fármacos , Agregación Plaquetaria/efectos de los fármacos , Transducción de Señal/efectos de los fármacos
6.
J Toxicol Sci ; 41(1): 123-8, 2016 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-26763399

RESUMEN

Paraphenylene daimine (PPD) is an aromatic amine that is widely used in several industrial products; however, its toxicity has been reported in several cases of cardiac arrests. As platelets play a key role in cardiovascular diseases, we aimed to determine the impact of PPD in vitro and in vivo on platelet function. Our findings demonstrated that platelet activation and aggregation were strongly enhanced by PPD. Treatment with PPD primed human platelets that became more reactive in response to low doses of collagen. Furthermore, PPD exacerbated thrombus formation in rats in comparison with those untreated. Our results suggest that PPD is an important platelet primer predisposing platelets to promote thrombus formation in response to vascular injury. This should prompt the authorities to consider controlling the marketing of this product.


Asunto(s)
Colágeno/farmacología , Fenilendiaminas/toxicidad , Agregación Plaquetaria/efectos de los fármacos , Trombosis/etiología , Animales , Femenino , Humanos , Técnicas In Vitro , Masculino , Activación Plaquetaria/efectos de los fármacos , Ratas Sprague-Dawley
7.
Front Immunol ; 6: 529, 2015.
Artículo en Inglés | MEDLINE | ID: mdl-26528290

RESUMEN

Inflammatory bowel disease (IBD) is a chronic and multifactorial disease of the gastrointestinal tract. The exact etiology of IBD remains complex and unclear involving an inadequately defined relationship between microbial insult, genetic predisposition, altered intestinal barrier permeability, oxidative stress components and abnormal immune responses. The role of the co-stimulatory system made up of cluster of differentiation 40 protein (CD40) and its ligand (CD40L) in the response of the immune system to pathogens is now widely accepted. The implication of CD40/CD40L axis in immune system disorders due to its important role as signal transduction pathway among immune cells is well documented. Several studies have suggested that CD40/CD40L interactions regulate oxidative stress; this can affect various signaling pathways leading to IBD development. Hence, CD40/CD40L signaling pathway may become a new target for IBD treatment. This review will cover the general contribution of the CD40/CD40L dyad in the development of IBD in order to facilitate future approaches aiming to elucidate the immunological mechanisms that control gut inflammation.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA